Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis

Abstract

Cystic fibrosis (CF) is a monogenic autosomal recessive disorder where the defective gene, the cystic fibrosis transmembrane conductance regulator (CFTR), is well identified. Moreover, the respiratory tract can be targeted through noninvasive aerosolized formulations for inhalation. Therefore, gene therapy is considered a plausible strategy to address this disease. Conventional gene therapy strategies rely on the addition of a correct copy of the CFTR gene into affected cells in order to restore the channel activity. In recent years, genome correction strategies have emerged, such as zinc-finger nucleases, transcription activator-like effector nucleases and clustered regularly interspaced short palindromic repeats associated to Cas9 nucleases. These gene editing tools aim to repair the mutated gene at its original genomic locus with high specificity. Besides, the success of gene therapy critically depends on the nucleic acids carriers. To date, several clinical studies have been carried out to add corrected copies of the CFTR gene into target cells using viral and non-viral vectors, some of them with encouraging results. Regarding genome editing systems, preliminary in vitro studies have been performed in order to repair the CFTR gene. In this review, after briefly introducing the basis of CF, we discuss the up-to-date gene therapy strategies to address the disease. The review focuses on the main factors to take into consideration when developing gene delivery strategies, such as the design of vectors and plasmid DNA, in vitro/in vivo tests, translation to human use, administration methods, manufacturing conditions and regulatory issues.

Keywords:

• Cystic fibrosis
• cystic fibrosis transmembrane conductance regulator
• gene therapy
• genome edition
• scale up

Acknowledgements

Authors wish to thank the intellectual and technical assistance from the ICTS “NANBIOSIS”, more specifically by the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) at the University of the Basque Country (UPV/EHU). I.V.B. thanks the Basque Country Government (Department of Education, University and Research) for the granted fellowship. This project was supported by the University of the Basque Country UPV/EHU (UFI 11/32) and the Basque Government (Department of Education, University and Research, predoctoral grant PRE_2015_2_0151).

Disclosure statement

The authors declare that they have no declarations of interest.

Additional information

Funding

This project was supported by the University of the Basque Country UPV/EHU (UFI 11/32) and the Basque Government (Department of Education, University and Research, predoctoral grant PRE_2015_2_0151).